Patents by Inventor Travis L. Houston

Travis L. Houston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of the menin-MLL interaction
    Patent number: 11479557
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: October 25, 2022
    Assignee: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20210053974
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: April 1, 2020
    Publication date: February 25, 2021
    Applicant: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
  • Inhibitors of the menin-MLL interaction
    Patent number: 10683302
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 16, 2020
    Assignee: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Choline cocrystal of epalrestat
    Patent number: 10464912
    Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 5, 2019
    Assignee: BIONEVIA PHARMACEUTICALS, INC.
    Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Travis L. Houston, Jeffrey S. Stults
  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20190144459
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 16, 2019
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • NOVEL CHOLINE COCRYSTAL OF EPALRESTAT
    Publication number: 20170174643
    Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventors: Isabel KALOFONOS, G. Patrick STAHLY, William MARTIN-DOYLE, Dimitris KALOFONOS, Travis L. HOUSTON, Jeffrey S. STULTS
  • Choline cocrystal of epalrestat
    Patent number: 9611234
    Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: April 4, 2017
    Assignee: BIONEVIA PHARMACEUTICALS, INC.
    Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Travis L. Houston, Jeffrey S. Stults
  • Solid forms of epalrestat
    Patent number: 9447056
    Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: September 20, 2016
    Assignee: BIONEVIA PHARMACEUTICALS, INC.
    Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
  • NOVEL CHOLINE COCRYSTAL OF EPALRESTAT
    Publication number: 20150057319
    Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
    Type: Application
    Filed: November 4, 2014
    Publication date: February 26, 2015
    Inventors: Isabel KALOFONOS, Patrick G. STAHLY, William Martin-Doyle, Dimitris KALOFONOS, Travis L. Houston, Jeffrey S. STULTS
  • Choline cocrystal of epalrestat
    Patent number: 8906948
    Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: December 9, 2014
    Assignee: Bionevia, LLC
    Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
  • Forms of rifaximin and uses thereof
    Patent number: 8815888
    Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: August 26, 2014
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston
  • NOVEL SOLID FORMS OF EPALRESTAT
    Publication number: 20140221438
    Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Applicant: Bionevia Pharmaceuticals, Inc.
    Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
  • Forms of rifaximin and uses thereof
    Patent number: 8754098
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: June 17, 2014
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
  • Solid forms of epalrestat
    Patent number: 8697735
    Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: April 15, 2014
    Assignee: Bionevia Pharmaceuticals, Inc.
    Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
  • NEW FORMS OF RIFAXIMIN AND USES THEROF
    Publication number: 20130317225
    Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.
    Type: Application
    Filed: July 31, 2013
    Publication date: November 28, 2013
    Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston
  • Forms of rifaximin and uses thereof
    Patent number: 8513275
    Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: August 20, 2013
    Assignee: Salix Pharmaceuticals, Ltd
    Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20130066079
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: August 23, 2012
    Publication date: March 14, 2013
    Applicant: Salix Pharmaceuticals, Ltd.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20120108620
    Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.
    Type: Application
    Filed: June 3, 2011
    Publication date: May 3, 2012
    Applicant: SALIX PHARMACEUTICALS, LTD.
    Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20120076857
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: September 6, 2011
    Publication date: March 29, 2012
    Applicant: SALIX PHARMACEUTICALS, LTD.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
  • Forms of rifaximin and uses thereof
    Patent number: 8067429
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: November 29, 2011
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston